Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is made up of three networks that monitor COVID-19, ...

Officials are encouraging Connecticut residents to get their updated shots before the holiday season begins. Unlike COVID-19 ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

Finance News; GSK trial proves RSV vaccine efficacy after three full seasons; GSK trial proves RSV vaccine efficacy after three full seasons ...

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant.

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting ...